Researchers report that RNA–protein interactions could provide new targets for coronavirus antiviral drugs. Two outlets describe a study led by researchers at the University of California, San Diego School of Medicine and the University of California, Riverside (UCR) School of Medicine, with a co-lead at UCR, suggesting these interaction sites may be useful for developing treatments.
The reporting also highlights an intended benefit: drug targets that may be less vulnerable to the viruses’ rapid evolution. While both articles focus on the same core finding—new antiviral targets derived from RNA–protein interactions—one frames the work more broadly as “could lead” to drug targets, while the other emphasizes the coronavirus context explicitly, including SARS‑CoV‑2, the virus that causes COVID‑19.
